KAIST and international collaborators have developed a CRISPR-based 'kinetic barcoding' method that distinguishes multiple viruses and variants in one test by measuring gene scissors' reaction speeds.
KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results